新型单克隆抗体药物治疗急性髓系白血病。

Novel monoclonal antibody-based therapies for acute myeloid leukemia.

机构信息

Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Pathology, University of Washington, Seattle, WA, USA.

出版信息

Best Pract Res Clin Haematol. 2019 Jun;32(2):116-126. doi: 10.1016/j.beha.2019.05.002. Epub 2019 May 9.

DOI:10.1016/j.beha.2019.05.002

PMID:31203993

Abstract

There has been long-standing interest in using monoclonal antibodies to improve outcomes of people with acute myeloid leukemia (AML). While several candidate therapeutics have failed at various stages of clinical testing, improved survival of some patients receiving the CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that monoclonal antibodies have a role in the armamentarium against AML. Over the last several years, work to improve the success of monoclonal antibody-based therapies in AML has focused on the identification and exploration of new antigen targets as much as on the development of novel treatment formats such as use of unconjugated engineered monoclonal antibodies and conjugated antibodies, delivering highly potent small molecule drugs or radionuclides to AML cells. Here, we will provide a brief overview of current efforts with such investigational monoclonal antibody-based therapeutics.

摘要

人们一直有兴趣使用单克隆抗体来改善急性髓细胞白血病（AML）患者的预后。虽然有几种候选治疗药物在临床测试的各个阶段都失败了，但一些接受 CD33 抗体药物偶联物吉妥珠单抗奥佐米星治疗的患者的生存率有所提高，这首次证明了单克隆抗体在对抗 AML 的武器库中具有作用。在过去几年中，为了提高基于单克隆抗体的治疗在 AML 中的成功率，研究工作主要集中在确定和探索新的抗原靶点上，同时也致力于开发新的治疗形式，如使用未偶联的工程化单克隆抗体和偶联抗体，将高效小分子药物或放射性核素递送到 AML 细胞中。在这里，我们将简要概述目前正在进行的此类研究性单克隆抗体治疗方法。